文献速递眼底病与葡萄膜炎青光眼

视网膜静脉阻塞的光凝治疗解读

Photocoagulation for retinal vein occlusion.
PubMed 文献 · Prog Retin Eye Res · 2021-03-11

本文综述了光凝在视网膜静脉阻塞(RVO)中应用的历史与证据,讨论其在缺血型视网膜中央静脉阻塞(CRVO)和视网膜分支静脉阻塞(BRVO)中对眼内新生血管(NV)及黄斑水肿的作用,并提及三项随机前瞻性临床试验,同时指出抗VEGF与皮质类固醇疗法已显著改变光凝的角色。

要点

  • 缺血型CRVO可并发眼内新生血管,非缺血型CRVO不并发。
  • 光凝曾用于预防和/或治疗眼内新生血管及新生血管性青光眼。
  • 抗VEGF与皮质类固醇疗法已大幅改变光凝在黄斑水肿和NV管理中的地位。

核心结论

  • 光凝在RVO中的作用需基于RVO分类、眼内NV及黄斑水肿自然病程来理解。
  • 缺血型CRVO的眼内NV是缺血性CRVO的并发症,非缺血性CRVO不发生。
  • 抗VEGF和皮质类固醇疗法的出现已彻底改变光凝在CRVO和BRVO黄斑水肿及NV管理中的角色。

研究设计与样本

  • 综述讨论了1974年以来光凝在RVO中作用的相关研究。
  • 文中讨论了三项涉及缺血型CRVO光凝的随机前瞻性临床试验。
  • 文中讨论了三项涉及BRVO眼内NV和黄斑水肿光凝的随机前瞻性临床试验。

主要发现

  • CRVO和BRVO最严重并发症为视力下降(多因黄斑水肿)和眼内NV(尤其新生血管性青光眼)。
  • 光凝被提倡用于预防和/或治疗眼内NV及NVG的发生。
  • 新生血管性青光眼是缺血型CRVO最可怕、难治且致盲的并发症。

临床怎么用

  • 临床需先区分CRVO为缺血型或非缺血型,因眼内NV仅见于缺血型CRVO。
  • 光凝在RVO管理中的角色应结合抗VEGF和皮质类固醇等新疗法重新评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of photocoagulation in retinal vein occlusion (RVO) has been studied since 1974. The most serious complications of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are: (i) visual deterioration, most commonly due to macular edema, and (ii) the development of ocular neovascularization (NV), particularly neovascular glaucoma (NVG), with hazardous consequences for vision and even the eye itself. Before discussing the role of photocoagulation in the management of NV and macular edema in RVO, it is crucial to gain a basic scientific understanding of the following relevant issues: classification of RVO, ocular NV in RVO, and the natural history of macular edema and visual outcome of RVO. These topics are discussed. In CRVO, ocular NV is a complication of ischemic CRVO but not of nonischemic CRVO. Photocoagulation has been advocated to prevent and/or treat the development of ocular NV and NVG. Since NVG is the most dreaded, intractable and blinding complication of ischemic CRVO, the role of photocoagulation and its management are discussed. Findings of three randomized, prospective clinical trials dealing with photocoagulation in ischemic CRVO are discussed. The role of photocoagulation in the management of ocular NV and macular edema in BRVO, and three randomized, prospective clinical trials dealing with those are discussed. Recent advent of intravitreal anti-VEGF and corticosteroid therapies has drastically changed the role of photocoagulation in the management of macular edema and NV in CRVO and BRVO. This is discussed in detail.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Hayreh SS. Photocoagulation for retinal vein occlusion. Prog Retin Eye Res. 2021. PMID: 33713810. doi:10.1016/j.preteyeres.2021.100964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。